Apatinib for the Elderly Advanced Gastric Cancer

• Status: Completed
• Trial end date: 2020-06-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of our study is to assess the efficacy and safety of apatinib in elderly advanced gastric cancer patients, and to find the relationship between the expression of VEGFR-2 and efficacy of apatinib treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Affiliated Hospital of Qinghai University
• Treatments: Apatinib

Criteria

Inclusion Criteria:

1. Elderly patients (aged ≥ 60 years) with histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction;

2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

3. Progression with or intolerance to one or more lines of chemotherapy;

4. At least one measurable lesion as defined by RECIST 1.1;

5. With acceptable hematologic, cardiac, hepatic, pulmonary and renal function;

6. Can take apatinib orally;

7. Estimated life expectancy ≥ 3 months.

Exclusion Criteria:

1. Patients cannot take apatinib orally for any reason;

2. Patients with uncontrolled central nervous system (CNS) metastases;

3. Patients with massive hydrothorax or ascites;

4. Proteinuria 2+ or 24-hour urinary protein ≥ 1g;

5. Newly-happened traumatism or pathological fracture;

6. Estimated life expectancy ˂ 3 months;

7. Received chemotherapy in the past 28 days before enrollment;

8. Patients with uncontrolled blood pressure on medication (≥ 140/90 mmHg);

9. Patients with bleeding tendency, receiving thrombolytics or anticoagulants, receiving intravenous antibiotic treatment, had received bevacizumab or other VEGF TKIs before, or with other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ).